Charles River Lifts 2026 Outlook and Targets 24% Margin by 2030
Charles River raised its 2026 outlook to the high end and set 2030 goals, targeting 5% to 7% organic growth, 24% margins, and $300M+ in cost savings.
biopharma
Charles River raised its 2026 outlook to the high end and set 2030 goals, targeting 5% to 7% organic growth, 24% margins, and $300M+ in cost savings.